# Vaccinex Reports 2025 Annual Financial Results
Canonical URL: https://biopharmsignal.com/news/VCNX/vaccinex-reports-2025-annual-financial-results
Ticker: VCNX
Company: Vaccinex
Source: Vaccinex
Published: 2026-04-30 00:05 EST
Original Source URL: https://ir.vaccinex.com
## Summary

ROCHESTER, N.Y., April 29, 2026 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (OTCMKTS:VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in Alzheimer’s, Huntington’s disease, and cancer today released financial results for the year ended December 31, 2025.

## Article Body
ROCHESTER, N.Y., April 29, 2026 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (OTCMKTS:VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in Alzheimer’s, Huntington’s disease, and cancer today released financial results for the year ended December 31, 2025.
## Recent Company News
- 2026-04-30 00:05 EST — [Vaccinex Reports 2025 Annual Financial Results](https://biopharmsignal.com/news/VCNX/vaccinex-reports-2025-annual-financial-results) — Source: Vaccinex
- 2025-12-23 13:01 EST — [Vaccinex, Inc. Announces $60 million Agreement to Finance a Phase 2b clinical trial of pepinemab to treat Alzheimer’s Disease](https://biopharmsignal.com/news/VCNX/vaccinex-inc-announces-60-million-agreement-to-finance-a-phase-2b-clinical-trial-of-pepinemab-to-treat-alzheimer-s-disease) — Source: Vaccinex
- 2025-05-27 12:45 EST — [Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting](https://biopharmsignal.com/news/VCNX/vaccinex-to-report-promising-new-clinical-results-of-neoadjuvant-treatment-with-pepinemab-to-enhance-immunotherapy-in-patients-with-head-and-neck-cancer-at-asco-annual-meeting) — Source: Vaccinex
- 2025-04-21 12:45 EST — [Vaccinex to Report Promising New Clinical Data Revealing Pepinemab’s Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)](https://biopharmsignal.com/news/VCNX/vaccinex-to-report-promising-new-clinical-data-revealing-pepinemab-s-unique-mechanism-to-enhance-immunotherapy-at-annual-meeting-of-american-association-for-cancer-research-aacr) — Source: Vaccinex
- 2025-03-07 22:15 EST — [Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market](https://biopharmsignal.com/news/VCNX/vaccinex-plans-to-delist-its-common-stock-from-the-nasdaq-stock-market) — Source: Vaccinex
## Related News
- 2026-07-21 20:15 EST — BFRG — [BullFrog AI to Participate in Water Tower Research Fireside Chat on Thursday, July 23, 2026](https://biopharmsignal.com/news/BFRG/bullfrog-ai-to-participate-in-water-tower-research-fireside-chat-on-thursday-jul-78357ce8)
- 2026-07-21 20:05 EST — CLPT — [ClearPoint Neuro to Announce Second Quarter 2026 Results August 3, 2026](https://biopharmsignal.com/news/CLPT/clearpoint-neuro-to-announce-second-quarter-2026-results-august-3-2026-6e4f3c05)
- 2026-07-21 20:05 EST — TCMD — [Tactile Medical to Release Second Quarter of Fiscal Year 2026 Financial Results on August 10, 2026](https://biopharmsignal.com/news/TCMD/tactile-medical-to-release-second-quarter-of-fiscal-year-2026-financial-results--798d4004)
- 2026-07-21 20:05 EST — PIII — [P3 Health Partners Schedules Second Quarter 2026 Earnings Release and Conference Call](https://biopharmsignal.com/news/PIII/p3-health-partners-schedules-second-quarter-2026-earnings-release-and-conference-6c9bd8a7)
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)